# A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain

Study · id `cardio:ct-nct02081690` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02081690](<https://clinicaltrials.gov/study/NCT02081690>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02081690

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 160 participants.

## Technical summary

Registry record NCT02081690. Allocation not applicable; no masking; primary purpose treatment. Start 2014-03-01 (actual); primary completion 2015-10-01 (actual). Results posted on 2018-02-05.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT02081690, source copy `cardio:ctgov-nct02081690-2018-03-21`, retrieved 2026-10-31)
- Started: 2014-03-01 (actual) (ClinicalTrials.gov record NCT02081690, source copy `cardio:ctgov-nct02081690-2018-03-21`, retrieved 2026-10-31)
- Primary completion: 2015-10-01 (actual) (ClinicalTrials.gov record NCT02081690, source copy `cardio:ctgov-nct02081690-2018-03-21`, retrieved 2026-10-31)
- Completion: 2015-11-01 (actual) (ClinicalTrials.gov record NCT02081690, source copy `cardio:ctgov-nct02081690-2018-03-21`, retrieved 2026-10-31)
- Results first posted: 2018-02-05 (ClinicalTrials.gov record NCT02081690, source copy `cardio:ctgov-nct02081690-2018-03-21`, retrieved 2026-10-31)
- Countries: France; Italy; Spain (ClinicalTrials.gov record NCT02081690, source copy `cardio:ctgov-nct02081690-2018-03-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02081690-2018-03-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
- Acronym: ORCHESTRA
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Macitentan
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

## Provenance

Content hash: df5f53653e80655e8cc32a5e1f6a9ea30c027a189f069f034c8d3097553f198a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
